6.19
Impella
®
System for Use During Cardiogenic Shock
ACCOUNTABILITY OF PMA COHORT
The study enrolled 17 patients at 7 enrolling sites from October 18, 2006 to June 4, 2008. The
overall enrollment for the RECOVER I trial is shown in Figure 6.15.
Figure 6.15 RECOVER I enrollment
AMI: Acute Myocardial Infarction; CABG: Coronary Artery Bypass Grafting; FDA: Food
and Drug Administration; MVR: Mitral Valve Repair or Replacement; OHT: Orthotopic
Heart Transplant; VAD: Ventricular Assist Device
STUDY BASELINE PARAMETERS
The baseline patient characteristics and hemodynamics are provided below.
Table 6.
5
Baseline patient characteristics
Patient Characteristic
RECOVER I Patients
(N=16)
[95% CI]
Age
Mean±SD (N)
58.38±8.94 (16)
[53.61,63.14]
Gender
Male
81.25% (13/16)
[54.35%,95.95%]
Weight (kg)
Mean±SD (N)
90.96±23.03 (16)
[78.69,103.23]
Height (cm)
Mean±SD (N)
174.21±10.36 (16)
[168.68,179.73]
BSA (m
2
)
Mean±SD (N)
2.05±0.28 (16)
[1.90,2.20]
Race
Caucasian
African American
Asian Pacific
50.00% (8/16)
31.25% (5/16)
18.75% (3/16)
[24.65%,75.35%]
[11.02%,58.66%]
[4.05%,45.65%]
6
C
LIN
IC
A
L E
X
P
E
RI
E
N
C
E
Summary of Contents for Impella 2.5
Page 4: ......
Page 8: ......
Page 10: ......
Page 12: ......
Page 15: ...2 WARNINGS AND CAUTIONS WARNINGS 2 1 CAUTIONS 2 3...
Page 16: ......
Page 22: ......
Page 38: ......
Page 40: ......
Page 108: ......
Page 171: ......
Page 173: ......
Page 181: ......
Page 183: ......
Page 201: ......
Page 203: ......
Page 205: ......
Page 210: ...INDEX TBD...